Impact of remdesivir according to the pre-admission symptom duration in patients with COVID-19.
Carolina Garcia-VidalRodrigo AlonsoAna M CamonCelia CardozoLaia AlbiachDaiana AgüeroM Angeles MarcosJuan AmbrosioniMarta BodroMariana ChumbitaLorena de la MoraNicole Garcia-PoutonGerard DueñasMarta Hernandez-MenesesAlexy InciarteGenoveva CuestaFernanda MeiraLaura MorataPedro Puerta-AlcaldeSabina HerreraMontse TusetPedro CastroSergio Prieto-GonzalezAlex Almuedo-RieraJosep MensaJosé Antonio MartínezGemma SanjuanJ M NicolasA Del RioJosé MuñozJordi VilaFelipe GarciaAlex Sorianonull nullPublished in: The Journal of antimicrobial chemotherapy (2021)
Patients with ≤3 days and 4-6 days from symptom onset to admission are associated with a 2.5- and 1.5-fold higher risk of death, respectively. Remdesivir was associated with 62% reduced odds of death versus standard-of-care and its survival benefit increased with shorter duration of symptoms.